Innovative Medicine
-
Johnson & Johnson Announces Commitment to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak
Up to 200,000 Regimens of Janssen’s Investigational Ebola Vaccine to be Supplied to Rwanda for Use in Border Region near Democratic Republic of the Congo (DRC) -
Johnson & Johnson Announces Winners of Champions of Science® Storytelling Challenge – Latin America and the Caribbean Edition
Program Spotlights Scientific Contributions and Personal Journeys of Scientists Across the Region -
New Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA® (canagliflozin) are Consistent Across Various Levels of Kidney Function
Analysis shows consistent renal and cardiovascular benefit when treated with INVOKANA® even when patients had moderate to severe renal deficiency INVOKANA® is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with type 2 diabetes (T2D) and DKD Data announcement comes after recent news of the company’s commercial partnership with Vifor Pharma, leader in nephrology, to jointly commercialize the INVOKANA® DKD indication in the United States -
TREMFYA® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies
Findings from the DISCOVER-1 and DISCOVER-2 studies are presented, for the first time, at the 2019 American College of Rheumatology and Association of Rheumatology Professionals Annual Meeting These are the first Phase 3 results evaluating p19-specific IL-23 inhibition in active psoriatic arthritis -
Johnson & Johnson Announces Submission of European Marketing Authorisation Applications for Janssen’s Investigational Ebola Vaccine Regimen
Data from multiple preclinical, Phase 1, 2 and 3 studies support applications, which have been granted Accelerated Assessment by European Medicines Agency -
Johnson & Johnson Announces Donation of up to 500,000 Regimens of Janssen’s Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC)
The government of the DRC supports use of Janssen’s vaccine regimen as part of expanded public health response to country’s Ebola outbreak – the second-worst on record -
New OPSUMIT® (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical and Functional Parameters in Patients with Pulmonary Arterial Hypertension
OPSUMIT, as part of a combination regimen, reduced the primary endpoint of mean pulmonary vascular resistance by 47% at week 16 compared with baseline -
Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative
In the Phase 3 pivotal trial, more than 40 percent of patients receiving STELARA subcutaneous (SC) injections every 8 weeks were in clinical remission at one year and not taking corticosteroids STELARA is the first and only approved treatment for ulcerative colitis to demonstrate improvement of the colon as measured by a novel histologic-endoscopic mucosal improvement endpoint -
Janssen Receives Positive CHMP Opinion for Spravato® (Esketamine) Nasal Spray for Adults with Treatment-Resistant Major Depressive Disorder
If approved by the European Commission, esketamine nasal spray will offer the first new mechanism of action in 30 years to treat major depressive disorder (MDD) In the phase III clinical development programme with flexible dosing, esketamine nasal spray and a newly initiated oral antidepressant achieved superior improvement in depression symptoms, and sustained improvement in their symptoms over time compared to adults who received a placebo and an oral antidepressant1,2